In 2021, the Chinese Center for Drug Evaluation of the National Medical Products Administration (NMPA) approved 764 Investigational New Drug (IND) applications of biopharmaceuticals. Almost 60 percent of all approved IND applications were ones concerning antineoplastic drugs.
Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021
Characteristic
Number of approved applications
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exclusive Premium Statistic
To access all Premium Statistics, you need a paid Statista Account
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
National Medical Products Administration. (June 1, 2022). Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021 [Graph]. In Statista. Retrieved July 28, 2024, from https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/
National Medical Products Administration. "Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021." Chart. June 1, 2022. Statista. Accessed July 28, 2024. https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/
National Medical Products Administration. (2022). Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021. Statista. Statista Inc.. Accessed: July 28, 2024. https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/
National Medical Products Administration. "Distribution of Therapeutic Areas for Approved Biopharmaceutical Investigational New Drug (Ind) Applications in China in 2021." Statista, Statista Inc., 1 Jun 2022, https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/
National Medical Products Administration, Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021 Statista, https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/ (last visited July 28, 2024)
Distribution of therapeutic areas for approved biopharmaceutical Investigational New Drug (IND) applications in China in 2021 [Graph], National Medical Products Administration, June 1, 2022. [Online]. Available: https://www.statista.com/statistics/1320129/china-therapeutic-for-approved-biopharmaceutical-ind-applications/